Multiple Myeloma Experience Survey - Teclistamab-daratumumab (TECVAYLI + DARZALEX) |
Introduction
We need your help!
Myeloma Canada is seeking information from people affected by multiple myeloma regarding a new treatment combination including teclistamab (TECVAYLI) and daratumumab (DARZALEX) (sometimes referred to as ‘tec-dara’), soon undergoing reimbursement review at Canada’s Drug Agency (CDA) and l'Institut national d’excellence en santé et en services sociaux (INESSS). CDA reviews oncology drugs approved for sale in Canada and makes funding recommendations to all provincial and territorial drug programs except Québec’s, while INESSS recommendations apply to Québec alone.
Sharing your experience can help decision-makers better understand how this treatment could benefit Canadians with myeloma.
This survey is intended for:
- Adults living with multiple myeloma and their care partners
AND
- Patients who have received or are currently receiving treatment with teclistamab-daratumumab and their care partners.
As always, patient and caregiver input is particularly important, and your participation can contribute to increasing Canadians' access to new myeloma treatments.
This survey should only take around 10 minutes of your time. We ask that the survey please be completed by August 2nd, 2026, 11:59 PM EST.
If you have any questions, please write to contact@myeloma.ca and indicate “Treatment Survey” in the subject line.
Thank you in advance for your participation and helping your fellow Canadians impacted by myeloma!
Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final report without reference to any identifying information.
If you have any questions, please write to contact@myeloma.ca and indicate “Treatment Survey” in the subject line.
Thank you in advance for your participation and helping your fellow Canadians impacted by myeloma!
Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final report without reference to any identifying information.